نتائج استخدام حاصرات بيتا في الفترة ما حول الجراحة عند مرضى الجراحات غير القلبية : مراجعة للدراسات السابقة المنشورة خلال العقد السابق

Abstract EN

Objective : we conducted this review to shed the light on the most recent studies related to using β-blockers for surgery as a factor that could enhance early and long-term prognosis, and to find out the advantages and disadvantages of using β-blockers and the best ways of using them in surgery.

methods : we surfed the medical web sites (Google Scholar, ELSEVIER, JAMA network, PubMed, NCBI, Cochrane) searching for studies involved in using β-blockers for surgical patients between 2010-2020, ignoring that which included only cardiac surgery or which depended in their results on scientifically wrong studies like (DECREASE family).

results: selective β1-antagonisme may be considered for non-cardiac surgery patients who have high cardiac risk -estimated using revised cardiac risk index (RCRI)- only with an obvious cardiac indication.

at urgent surgeries, exposure should not be less than 48 h; and β-antagonism dosage should be titrated depending on blood pressure and heart rate for selective surgeries and should be sustained after surgery.

we should make in-depth studies about using β-blockers for patients who will have crucial doubt regarding blood transfusion in hemorrhagic surgeries; especially with patients exposed to β-blockers.

conclusions: it is better not to use β-blockers for non-cardiac surgery patients and choose the selective ones when there is an obvious cardiac indication.

however, β-blockers may enhance surgical prognosis only in specific groups of patients.